Q-omics provides the consensus-scored ANKRD24 profile across patient tissues and cancer cell-line models. ANKRD24 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ANKRD24 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, ANKRD24 RNA expression shows 16,510 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, KICH, and TGCT as cancer lineages where ANKRD24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD24 survival associations across molecular data types. ANKRD24 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD24 RNA expression–survival associations across cancer types. High ANKRD24 expression shows unfavorable associations in COAD and LAML, but favorable associations in LIHC, BRCA, BLCA and SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ANKRD24 RNA expression.
This table summarizes ANKRD24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD24 shows lower tumor expression in KICH, THCA, UCEC, LUSC and CHOL and higher tumor expression in KIRP. The KICH box plot shows higher ANKRD24 RNA expression in normal versus tumor tissue (log2 FC = −1.190, t-test p < 0.001).
This table shows molecular features associated with ANKRD24 in patient tissues and cancer cell lines. In patient samples, ANKRD24 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
